Intrarosa will not only expand and strengthen our product portfolio into Women's Health in Canada but will cater to satisfy the unmet medical needs.
The appointments come as Andrew Paterson, who has spent 31 years with the company, prepares to retire
Clearing 19 biologics for Europe market
The move makes EBGLYSS the only therapy offering as few as six maintenance injections per year
The conference highlighted research suggesting that deuterium levels may influence key biological processes
The product has received tentative USFDA approval, Health Canada notice of compliance, and Indian regulatory approval
Backed by Semaglutide launches, the company reported 47% quarter-on-quarter revenue growth in Q4 FY26, with EBITDA expanding more than fivefold
NEJM study shows strong protection across strains
LIR Life is working on a patch-based, transdermal delivery system for GLP-1 therapies targeting obesity
Approval strengthens the company’s growing international anti-infective portfolio
Subscribe To Our Newsletter & Stay Updated
